OUTCOME IN INFANTS WITH A FAMILY HISTORY OF AUTISM AND ADHD

Published in JCPP Advances 02/08/2023: https://doi.org/10.1002/jcv2.12189

Three Year Outcomes in Infants with a Family History of Autism and/or Attention Deficit Hyperactivity Disorder (ADHD)

Tony Charman*, Greg Pasco1, Alexandra Hendry2#, Tessel Bazelmans1#, Nisha Narvekar1#, Amy Goodwin1#, Hanna Halkola1#, Mary Agyapong1#, Rebecca Holman3#, Jannath Begum Ali3#, Mutluhan Ersoy4#, Mark H. Johnson3,5, Andrew Pickles1, Emily J.H. Jones3, & The STAARS Team†

1Institute of Psychiatry, Psychology & Neuroscience, King’s College London, UK
2Department of Experimental Psychology, University of Oxford, UK
3Centre for Brain and Cognitive Development, Birkbeck, University of London, UK
4Department of Psychology, Kastamonu University, Turkey
5Department of Psychology, University of Cambridge, UK

† STAARS Team authors listed in Acknowledgements

# Order of indicated authors randomly generated

Running head: OUTCOME IN INFANTS WITH A FAMILY HISTORY OF AUTISM AND ADHD

Word count: Title page, Abstract, References, Main text, Acknowledgements, Tables, and Figures = 8,435
Word count: Title page, Abstract, Main text = 5,594
Abstract

Background: Most research on early outcomes in infants with a family history of autism has focused on categorically defined autism, although some have language and developmental delays. Less is known about outcomes in infants with a family history of attention deficit hyperactivity disorder (ADHD).

Methods: Infants with and without a family history of autism and / or ADHD, due to a first-degree relative with either or both conditions, were recruited at 5 or 10 months. Three year outcomes were characterised using latent profile analysis (LPA) across measures of cognitive ability, adaptive functioning and autism, ADHD and anxiety traits \((n = 131)\). We additionally ran an LPA using only autism and ADHD measures, and the broader LPA in an independent cohort \((n = 139)\) and in both cohorts combined \((n = 270)\).

Results: A Low Developmental Level + High Behavioural Concerns class had elevated autism, ADHD and anxiety scores, low cognitive and adaptive function, and included all but one child with autism. A Low Developmental Level + Typical Behaviour class had average cognitive ability and typical behaviour but low adaptive function. A Typical Developmental Level + Some Behavioural Concerns class had average cognitive and adaptive function but slightly elevated behaviour scores. A High Developmental Level + Typical Behaviour class had above average cognitive ability and typical behaviour. All four LPAs identified classes characterised by combinations of either, or both, Low Developmental Level and elevated behaviour scores, as well as a typically developing class. No classes had elevated autism or ADHD traits in isolation.

Conclusions: Some infants with a family history of autism or ADHD have atypical developmental and behavioural outcomes, but do not show strong autism or ADHD traits in isolation. The field needs to recalibrate aims and methods to embrace the broader transdiagnostic pattern of outcomes seen in these infants.
Keywords: autism, ADHD, infancy, early childhood, latent profile analysis

Abbreviations: LPA: latent profile analysis
Autism is a strongly heritable condition (Tick et al., 2016). Against a population prevalence of ~1–2% (Maenner et al., 2020) sibling recurrence rates in clinically ascertained cohorts are approximately 10% (Hansen et al., 2019). Attention deficit hyperactivity disorder (ADHD) is also highly heritable (Thapar & Cooper, 2016). Its prevalence is ~3–5% (Polanczyk et al., 2015) but clinically-ascertained sibling recurrence rates for later-born siblings are also ~10% (Miller, Musser, et al., 2019). Autism and ADHD commonly co-occur at both the clinical and the trait level (Hollingdale et al., 2020; Miller, Musser, et al., 2019). Twin and family studies show moderate shared heritability between the two conditions (Ghirardi et al., 2019; Taylor et al., 2013). Consistent with this, siblings of children with autism have elevated rates of ADHD and, conversely, siblings of children with ADHD have elevated rates of autism (Ghirardi et al., 2019; Jokiranta-Olkoniemi et al., 2016; Miller, Musser, et al., 2019). Understanding the aetiology of this co-occurrence has important implications for science and clinical practice (Thapar et al., 2017). Prospective infant designs may provide new insights into this co-occurrence. Infants are not recruited based on an existing diagnosis of either, or both, autism and ADHD but on the basis of family history. Studying development in infancy before clear manifestations of the behaviours that define autism and ADHD have emerged may help us to identify shared and distinct neurodevelopmental pathways to each condition, both in isolation and in combination (Johnson et al., 2015).

In prospective studies of infants with a family history of autism, recurrence rates of autism are ~20% (Messinger et al., 2015; Ozonoff et al., 2011). However, there is also an increased rate of broader atypical outcomes beyond an autism diagnosis. Subclinical autism traits, and lower cognitive, language and adaptive ability characterise ~20% of infants who do not have an autism diagnosis (Charman et al., 2017; Marrus et al., 2018; Messinger et al., 2013; Ozonoff et al., 2014). Few studies have reported the rates of intellectual disability and
language delay in prospectively-studied infants who have autism, but group-level data from large cohorts suggests these rates are significant (e.g., Table 2, Zwaigenbaum et al., 2021; Figure 2, Messinger et al., 2015).

Fewer studies have reported on early developmental outcomes in prospectively-studied infants with a family history of ADHD, and findings are more preliminary (Johnson et al., 2015). One recent study of infants with a family history of autism or ADHD characterised clinical outcomes at 3 years. Miller et al. (2020) used latent profile analysis (LPA) of observation and parent-report measures of autism and ADHD traits and identified three outcome classes: an autism class (with both high autism and ADHD traits), an ADHD class (with high ADHD traits but low autism traits), and a typically developing class. In the same cohort, Reetzke et al. (2021) reported clinically derived outcome groups, comprising those with an autism diagnosis and those with ‘ADHD concerns’ based on a combination of researcher clinical best estimate (CBE) and parent and teacher report of ADHD traits. Miller et al. (2020; Table 3) show high correspondence between the LPA data-derived autism class and a CBE autism judgement but only moderate correspondence between the ADHD classifications, with significant proportions of those identified in the LPA ADHD class having a CBE of autism or no concerns. To date, no study has reported on broader developmental and behavioural outcomes in a cohort of infants with a family history of ADHD.

*The current study*

The extant literature on infants with an autism family history, and the wider literature on family recurrence of neurodevelopmental conditions, suggests that family liability is not specific to autism or to ADHD. Transdiagnostic approaches to understanding early developmental psychopathology are important due to the shared liability factors and high co-occurrence of these conditions but also because they reflect presentations seen in clinical
settings (Astle et al., 2022; Talbott & Miller, 2020; Thapar et al., 2017). In line with this, in the current study we characterised outcome in infants at elevated familial likelihood of autism and ADHD, due to having a first-degree relative with either or both conditions, by classes defined using LPA across measures of cognitive ability, adaptive behaviour and early autism, ADHD and anxiety traits. We also conducted an analysis similar to Miller et al. (2020) using only autism and ADHD measures and replicated our broader LPA in an independent cohort and in both our cohorts combined. We expected to identify a class of children with autism and broader atypical development and behaviour. We examined whether additional group(s) with atypical outcomes existed and if these showed predominantly elevated early ADHD traits or broader developmental and behavioural difficulties.

Methods

Participants

Infants at either 5 or 10 months of age were enrolled if they had a first-degree relative with a community clinical diagnosis of autism, a first-degree relative with a community clinical diagnosis of ADHD or elevated ADHD traits, or both. Parental report of an existing clinical diagnosis of autism and / or ADHD in an older sibling (proband) was the most common route. Some parents reported that they themselves had a diagnosis of either condition or they or their older child had suspected ADHD following which screening with a short version of one the Conners suite of measures was employed (see Supplementary Materials Appendix S1, Table S1 and Table S2). Comparison infants with no family history of either condition and a typically developing older sibling were also recruited. Inclusion criteria also included full-term birth (gestational age > 36 weeks) and no known medical or developmental condition. Informed written consent was provided by parents/carers. The total sample ($n = 161$) comprised 80 infants with a first-degree relative (family history (FH)) with autism only (FH-Autism), 31 infants with a first-degree relative with ADHD only (FH-ADHD), 21
infants with first-degree relatives with both autism and ADHD (FH-Autism + ADHD), and 29 infants with no first degree relative with either condition (typical likelihood (TL)) (Table S3). Of these, 131 infants (81.4%) had at least one outcome measure used in the LPA (see below) and are included in the current analysis: 67 FH-Autism, 26 FH-ADHD, 16 FH-Autism + ADHD, and 22 TL (Table 1).

3 Year Outcome Measures

The Mullen Early Learning Composite (ELC) (Mullen, 1995) – derived from Expressive language, Receptive language, Visual reception and Fine motor subscales – and the Vineland-II Adaptive Behavior Composite (ABC) (Sparrow et al., 2005) – derived from Socialization, Communication, Daily Living Skills and Motor domains – were administered as measures of cognitive ability and adaptive functioning, respectively.

The Autism Diagnostic Observation Schedule-2 (ADOS-2; Lord et al., 2012), Autism Diagnostic Interview-Revised (ADI-R; Lord et al. 1994) and the Social Communication Questionnaire (SCQ; Rutter, Bailey, & Lord, 2003) were administered. Autism traits were also measured with the Social Responsiveness Scale 2-Preschool Form (SRS-2; Constantino & Gruber, 2012). Best estimate DSM-5 clinical diagnosis of Autism Spectrum Disorder (ASD) was informed by, but not dependent on, scores on the ADOS-2, ADI-R, SCQ, Vineland-II, and Mullen, and researcher observations and parent-reported information, by experienced researchers (TC, GP).

Emerging ADHD and anxiety traits were measured using the parent-report DSM subscales of the Child Behaviour Checklist-Preschool (CBCL-P 1.5-5; Achenbach & Rescorla, 2000). An observational measure of early ADHD behaviours (attentiveness, activity level, and inhibition to objects/the environment; scored on a 7 point Likert scale) was completed using consensus coding by researchers based on observations made across the visit.
Statistical analysis

We conducted latent profile analysis (LPA) using continuous indicator variables to identify homogeneous classes based on the following 3 year outcome variables: Mullen ELC, Vineland ABC, ADOS-2 CSS, SCQ total score, researcher early ADHD observation total score, and CBCL ADHD and anxiety subscale raw scores. Variables were modelled, conditional on latent class, using Poisson distributions for all variables except SCQ where overdispersion required a negative binomial distribution. LPA was performed using the gsem command in Stata 16 (StataCorp., 2019) on the whole sample with at least one of the seven outcome measures available (n = 131; 122 children had ≥ 4 measures, 4 ≥ 3, 3 ≥ 2, and 2 children 1 measure only). Models were estimated using maximum likelihood to account for data missing at random. To select the “best fitting” solution we examined conventional likelihood-based (Bayesian information criterion (BIC)) and classification-based (Integrated Classification Likelihood (ICL); entropy) fit statistics (Henson et al., 2007); the proportion of participants represented in each class; and the extent to which classes captured clinically meaningful subgroups of participants (Nylund et al., 2007). Individuals were assigned to classes based on the maximum aposterior probability of class membership (MAP).

We named the outcome classes in terms of developmental level (cognitive ability and adaptive function) and behaviour (autism, ADHD and anxiety traits) – namely the indicator variables from which they were derived. We compared the scores of the outcome classes using ANOVA with post-hoc Tukey-Kramer corrections to account for unequal cell sizes and tested sex differences in class assignment using chi-square tests followed by post-hoc residuals adjusted for the sample size of each group (Kirk, 1998). The high values of MAP we report made more complex multi-step post-assignment analysis methods unnecessary.

Results
Three- and four-class solutions had similar entropy values (0.82 and 0.80, respectively) and the best fit statistics (BIC = 4486.24, ICL = 4537.94 and BIC = 4484.21, ICL = 4555.60, respectively; Table S4). We chose the four-class solution as providing the most robust and clinically meaningful distribution of classes, with a minimum class size comprising 15.6% (n = 20) of the sample and average MAP values for each class all \( \geq 0.83 \). Table S5 shows the correlations between the class indicator variables and R-squared values from regressing each indicator onto the set of classes.

Scores of the four-classes on the outcome measures used to derive the classes are shown in Table 2\(^1\) and Figure 1. Based on the pattern across the measures we labelled the classes: *Low Developmental Level + High Behavioural Concerns* (LDL+HBC; \( n = 20, 16\% \)), *Low Developmental Level + Typical Behaviour* (LDL+TB; \( n = 23, 19\% \)), *Typical Developmental Level + Some Behavioural Concerns* (TDL+SBC; \( n = 33, 24\% \)), and *High Developmental Level + Typical Behaviour* (HDL+TB; \( n = 55, 42\% \)).

----- Table 2 and Figure 1 ----- 

ANOVA\(\)s and Tukey-Kramer post-hocs for class differences are in line with class identification. The LDL+HBC class had elevated autism, ADHD and anxiety scores, low cognitive ability and adaptive function. The LDL+TB class had low autism, ADHD and anxiety scores, average cognitive ability but below average adaptive function. The TDL+SBC class had average cognitive ability and adaptive function but slightly elevated scores on the SCQ and the CBCL ADHD and anxiety subscales. The HDL+TB class had low autism, ADHD and anxiety scores, above average cognitive ability and average adaptive function. When considered in terms of the proportion of each class falling above or below clinical thresholds (> 1SD for standardised scores and T-scores; above the autism threshold

\(^1\) Table 2 shows T-scores for the CBCL measures for descriptive purposes but raw scores were entered into the LPA analysis.
on the ADOS-2 and SCQ\(^2\) the pattern was similar (Table 3). Thirteen children met diagnostic criteria for autism – 12 were identified in the LDL+HBC class and 1 in the TDL+SBC class\(^3\).

Table 4 shows the association between the derived classes and the autism and ADHD FH sampling frame and sex. All children in the LDL+HBC and LDL+TB classes were from the family history groups. Children from the TDL+SBC and HDL+TB classes were from all the sampling groups. Boys were over-represented in the LDL+HBC and LDL+TB classes but these differences were non-significant (overall chi-square p=.18).

We ran a second LPA using only measures of autism and ADHD (ADOS-2 CSS, SCQ total score, researcher ADHD observation total score, and CBCL ADHD raw score). The three-class solution provided the most robust and clinically meaningful distribution of classes, with a minimum class size comprising 17.0% (n = 20) of the sample and average MAP values for each class all ≥ 0.84 (Table S6). The identified classes were: High Behavioural Concerns (HBC; n = 20, 17%), Slight Behavioural Concerns (SBC; n = 72, 54%), and Typical Behaviour (TB; n = 37, 29%). These 3 classes are similar to those identified by the LPA with a broader set of indicator variables except that the class with LDL+TB was not identified, reflecting the fact that Mullen and Vineland were not indicators. The HBC class had elevated autism and ADHD scores on the measures used to derive the classes and included all 12 children\(^4\) with an autism diagnosis. However, when examining scores on the other measures not used to derive the classes they also had elevated anxiety scores, low cognitive ability and low adaptive function (Table S7).

\(^2\) We used the ≥ 12 threshold on the SCQ for 3 year olds (Corsello et al., 2007)
\(^3\) We note that only 48% of children with elevated ADHD scores and 36% of children with elevated anxiety scores had an autism diagnosis
\(^4\) One fewer child with autism had at least one of more restrictive list of outcome class indicators
We repeated the broader LPA analysis in an independent cohort of \( n = 139 \) infants with a FH of autism and/or ADHD with outcome data at 3 years using the Mullen ELC, Vineland ABC, ADOS-2 CSS, SCQ total score, and CBCL ADHD and anxiety subscale raw scores\(^5\). The four-class solution provided the most robust and clinically meaningful distribution of classes, with a minimum class size comprising 17.0\% (\( n = 20 \)) of the sample and average MAP values for each class all \( \geq 0.91 \) (Table S8). Based on the pattern across the measures we labelled the classes: *Low Developmental Level + High Behavioural Concerns* (LDL+HBC; \( n = 21, 15\% \)), *Typical Developmental Level + High Behavioural Concerns* (TDL+HBC; \( n = 27, 19\% \)), *Low Developmental Level + Typical Behaviour* (LDL+TB; \( n = 20, 14\% \)), and *High Developmental Level + Typical Behaviour* (HDL+TB; \( n = 71, 51\% \)) (See Appendix S2, Table S9, Table S10, Table S12 and Figure S1). Sixteen children met diagnostic criteria for autism: 10 of these were identified in the LDL+HBC class, 5 in the TDL+HBC class, and 1 in the LDL+TB class. Girls were over-represented in the HDL+TB class (\( p < .01 \)) and boys in the LDL+HBC (\( p < .01 \)) and LDL+TB (\( p < .05 \)) classes (Table S11).

We then repeated the broader LPA in the combined sample of both cohorts (\( n = 270 \)). Similar LDL+HBC and HDL+TB classes to those described above emerged. A second atypical *Low Developmental Level + Typical Behaviour* (LDL+TB) class had slightly low cognitive ability and adaptive function but did not have elevated scores on autism, ADHD or anxiety measures. A *Typical Developmental Level + Some Behavioural Concerns* (TDL+SBC) class had slightly elevated scores on ADHD and anxiety measures and on the SCQ but not the ADOS, high average cognitive ability and average adaptive function. These patterns were reflected both in terms of group means (Table S13, Figure S2) and the proportion of the class scoring above or below the 1SD and clinical thresholds (Table S14;\(^5\))

---

\(^5\) The researcher ADHD observation measure was not completed in this cohort
OUTCOME IN INFANTS WITH A FAMILY HISTORY OF AUTISM AND ADHD

Appendix S3, correlations shown in Table S16). Twenty eight children met diagnostic criteria for autism: 19 in the LDL+HBC class, 8 in the TDL+SBC class, and 1 in the LDL+TB class. Girls were over-represented in the HDL+TB class (p < .01) and boys in the LDL+HBC (p < .05) and LDL+TB (p < .05) classes (Table S15).

Discussion

We used a data-driven approach to identify outcome classes across measures of cognitive ability and adaptive functioning, and autism, ADHD and anxiety traits, at 3 years in infants with a family history of autism or ADHD, or both. We identified a class with elevated autism, ADHD and anxiety scores, low cognitive ability and adaptive function, which included most children with an autism diagnosis. A second atypical class had low autism, ADHD and anxiety scores, average cognitive ability but below average adaptive functioning; and a third atypical class had average cognitive ability and adaptive function but slightly elevated behavioural scores. A typically developing class with above average cognitive ability was also identified.

In an independent cohort, we also identified three atypical classes with overlapping but slightly different profiles: two with high behaviour scores, one with low cognitive ability and one average cognitive ability, and a third class with low cognitive ability but typical behaviour, although this class had elevated ADOS scores most likely reflecting their developmental delay. Boys were over-represented in the atypical outcome classes compared to girls and whilst this did not reach significance in our primary analysis it did in the independent cohort and both cohorts combined. When an LPA was conducted in the combined sample, one typically developing class with above average cognitive ability was found. Atypical classes comprised one with LDL+HBC that included most children with autism; another with slightly low cognitive ability and adaptive behaviour; and a third atypical classes with typical cognitive ability and slightly elevated ADHD, anxiety and
autism scores. Across all analyses no outcome class with elevated autism or ADHD traits in isolation was found.

When only measures of autism and ADHD were used as class indicators we identified a similar (largely overlapping) class that had elevated autism and ADHD behaviours but also elevated anxiety and below average cognitive ability and adaptive function on measures that were not used to derive the LPA classes. Even when considering this class only in terms of the autism and ADHD indicator variables used in the LPA they had both elevated autism and ADHD scores. One other class had very slightly elevated scores on the parent-report SCQ and CBCL-ADHD subscale and another class typical behaviour. This pattern differs from Miller et al. (2020) who used a similar data-driven LPA approach to characterise outcome classes at 3 years in infants with a family history of autism or ADHD. Miller et al. identified an autism class, which also had elevated ADHD scores and low cognitive ability (p.1327 and Table S2, Miller et al., 2020), an ADHD class who had slightly but not clinically elevated autism scores on the SCQ and the ADOS-2 and average cognitive ability, and a typically developing class6. We did not identify a class with elevated ADHD scores only, even in the LPA model using only autism and ADHD measures to derive classes. There are several differences between the studies that may in part explain these discrepancies. In terms of recruitment, Miller et al. (2020) created separate ADHD and autism family history groups and infants with a family history of both autism and ADHD were allocated to the autism family history group, whereas we treated family history of autism and ADHD alone and in combination independently. Whilst both studies used the ADOS and the SCQ as autism indicator variables in their LPA, Miller et al. used different researcher- and parent-rated measures of ADHD to the current study.

Approaches to characterising outcomes in infants with a family history of autism and / or

---

6 We are very grateful to Dr. Meghan Miller for generously sharing unpublished data from Miller et al. (2020)
Although we found moderately high recurrence rates of autism in our samples (10% in the primary sample, 12% in the independent sample), autism in isolation is not the primary atypical outcome in early childhood of infants with an autism family history (with or without an ADHD family history). This is neither a new nor a surprising finding. In clinical samples both autism and ADHD commonly co-occur with other neurodevelopmental and neuropsychiatric conditions. Studies of older siblings and family members show not only that autism and ADHD commonly co-occur (Miller, Musser, et al., 2019; Musser et al., 2014) but also that in siblings of children with autism and ADHD other neurodevelopmental and neuropsychiatric conditions including anxiety, conduct disorder, intellectual disability and language delay are also common (Jokiranta-Olkonimi et al., 2016, 2019). This is consistent with the atypical outcome classes we identified in all four analyses conducted where a combination of either, or both, broader atypical behaviour and low cognitive and / or adaptive function was seen across the classes. In studies of autism family history infants many of those who have autism at 3 years have low cognitive ability and adaptive behaviour (Messinger et al., 2015; Zwaigenbaum et al., 2021). Consistent with previous studies, both in infants with autism and those without (Messinger et al., 2013, 2015), we found boys to be over-represented in the classes with lower developmental level and higher behavioural concerns.

In infants with an autism family history who do not have autism ~20% are characterised by elevated but sub-clinical autism traits, low cognitive, language and adaptive ability (in combination sometimes referred to as the ‘broader autism phenotype’ or ‘other developmental concerns’), and also elevated rates of emotional and behavioural problems (Charman et al., 2017; Marrus et al., 2018; D. Messinger et al., 2013; Miller, Iosif, et al., 2019; Ozonoff et al., 2014). In most previous autism family history infant studies, including
Ours, the group of children who meet diagnostic criteria for autism at 3 years are labelled the ‘autism outcome’ group. Clearly a group of children who do meet the diagnostic criteria for autism exist, and without exception children with an autism diagnosis were in the atypical LPA classes identified here. However, the use of the singular ‘autism’ term to describe this group may inadvertently overshadow their broader profile of developmental and behavioural atypicality, as well as the fact that they share many characteristics with children who may fall just below the clinical threshold for a diagnosis.

We chose to name the outcome classes identified in terms of developmental level (cognitive ability and adaptive function) and behaviour (autism, ADHD and anxiety traits) – namely the indicator variables from which they were derived. Since our focus was on broader transdiagnostic characterisation of developmental and behavioural outcomes in the cohorts at 3 years and not categorical diagnosis we have described the developmental outcomes as ‘low’, ‘typical’ and ‘high’ developmental level and the behavioural outcomes as ‘typical behaviour’ and ‘some’ or ‘high’ ‘behavioural concerns’. These do not equate to clinical classifications and we did not apply a strict threshold for their application – in part because across the LPAs we ran classes often had slightly different profiles of scores across the individual measures. We have used terminology and concepts from the developmental psychopathology / child psychiatry field to describe the outcome classes since ‘developmental level’ and ‘behavioural concerns’ map directly onto the indicator measures used to form LPA classes (Mullen and Vineland, and ADOS, SCQ and CBCL, respectively) and align with both previous literature and conventional clinical usage. However, we acknowledge the changing conceptual and linguistic landscape in the field and the outcome groups could alternatively be labelled as showing moderate or high ‘neurodivergent’ development (Dwyer, 2022; Sonuga-Barker & Thapar, 2021).
However, inspection of both the mean scores and the proportions of each identified class falling above or below the clinical cut-points on screening and diagnostic measures, or +/- 1SD on standardised measures, indicate that the atypical classes identified have partially distinct but also partially overlapping profiles. This approach is similar to that adopted in previous studies (e.g. Charman et al., 2017; Messinger et al., 2013; Miller et al., 2020). Children with elevated autism, ADHD and anxiety traits at this age may not meet the threshold for a clinical condition nor necessarily require intervention or support.

Notwithstanding this, across the current analyses between 50% and 60% of the infants with a family history of autism and/or ADHD were identified in one of the atypical classes. Given the family history nature of the cohorts and the fact that here we characterise outcomes only up to age 3 years it will be important to study and monitor these children as they grow older.

**Implications for the study of family history infants**

The findings of the present analysis go beyond nomenclature and should influence the motivation, design, analysis and interpretation of future family history studies. For example, the broader transdiagnostic pattern of atypical neurodevelopmental outcomes we have identified has important implications for studies that aim to identify early biomarkers and endophenotypes of autism (Johnson et al., 2015; Jones et al., 2014; Szatmari et al., 2016; Wolff & Piven, 2021). Although many infant signs and biomarkers have been mooted (and some patented) as predicting later autism, if the ‘natural categories’ of early outcome in infants with a family history are broader – both across autism versus other behavioural phenotypes (here, ADHD and anxiety) and across behavioural versus developmental outcomes (here, cognitive ability and adaptive behaviour) – then there needs to be a recalibration of aims and methods. These cautions also apply to mechanistic interpretations where infant experimental signals are taken to be precursors of later social communication, repetitive or sensory behaviours, without addressing the extent to which they may be
confounded by cognitive ability, adaptive function or later emerging ADHD or anxiety traits. This may motivate research groups, including ours, to re-analyse previously published findings to test the specificity of prediction to autism vs. other atypical neurodevelopmental outcomes.

Other important future goals include examining whether there is greater differentiation of the developmental and behavioural phenotypic pattern we have observed at age 3 years as children are followed to mid-childhood (e.g. Shephard et al., 2017) and exploring the age and the indicators in the infancy period that might identify children who will later develop this presentation (e.g. Kostyrka-Allchorne et al., 2020).

Strengths and limitations

The study has several strengths. In a moderate size sample of infants with an autism and/or ADHD family history followed to age 3 years we have used a data-driven approach to derive outcomes employing a broad range of developmental and behavioural measures rather than only autism symptoms. We replicated our approach in an independent sample and in both samples combined. However, this latter sample was recruited based on an established family history of autism and while information on family history of ADHD was collected this was not an integral part of the recruitment. Limitations include that we only studied outcomes through to 3 years. The characterisation of ADHD, anxiety and other neurodevelopmental outcomes – as well as autism itself (Ozonoff et al., 2018) – is incomplete at this age (Rocco et al., 2021) and further work is needed to develop and validate accurate and reliable measures of different forms of emerging developmental psychopathology in the early years. We have previously followed autism family history infants to mid-childhood and found elevated levels of ADHD and anxiety traits both in those children with an autism diagnosis and those without (Shephard et al., 2017). We did not obtain sufficient information at 3 years to ascertain ADHD diagnoses. A number of measures
employed in the current study are parent-report and suffer from potential shared methods and reporting bias limitations. Examination of the regressions of LPA indicator variables onto the LPA class solution shows that these measures (and also the direct Mullen assessment) were most strongly correlated with the identified classes, and that whilst the observational measures (ADOS and researcher ADHD ratings) contributed significantly the correlations were notably weaker. Another, related limitation of reliance on parental report questionnaires is the ability both of parents and the questionnaires themselves to distinguish between specific behaviours that may be manifestations of different emerging difficulties (see Hus et al., 2013). Finally, our researcher observational measure of early ADHD behaviours was not a standard measure, observers were not blind to family history, and whilst we conducted researcher consensus ratings no inter-rater reliability data was collected.

Conclusions

Family history, twin and genetic studies suggest that family liability is not specific to autism or to ADHD. There is overlap in early genetic liabilities related to the later expression of both phenotypes (Constantino et al., 2021), and autism and ADHD (and other early neurodevelopmental phenotypes) are underpinned by partially overlapping and partially separate developmental processes (Johnson et al., 2015, 2021; Miller et al., 2020). Much progress has been made in understanding the early development of autism, including from infant family history studies, and recent progress is apparent in the early ADHD field (Miller et al., 2023). However, if as we demonstrate here, the ‘natural categories’ of atypical outcome of infants with a family history of autism and / or ADHD are not the autism and ADHD phenotypes in isolation, but broader atypical developmental and behavioural outcomes, then the field needs to embrace this challenge. This concept is similar to that identified previously by Gillberg (2010) as ‘ESSENCE’ (Early Symptomatic Syndromes Eliciting Neurodevelopmental Clinical Examinations). Gillberg argued that early
manifestations of neurodevelopmental conditions (seen in clinic) are commonly non-specific, affecting motor, cognitive, communicative and social development, as well as sleep, feeding and behavioural regulation.

Research on developmental models and approaches to clinical translation should adopt a transdiagnostic approach in developmental studies of early autism and ADHD. Initial suggestions include the need to explicitly test the ‘phenotype-specificity’ of early infant neurodevelopmental markers of later outcomes; and the development of pre-emptive interventions that promote broader developmental competencies and outcomes, rather than targeting emergent symptoms of specific neurodevelopmental conditions (Constantino et al., 2021; Manzini et al., 2021). One critical question is whether at this age atypical development is truly transdiagnostic, akin to the ESSENCE concept, and may only differentiate later in development; or whether developmental ability, autism, ADHD and anxiety are separable but simply cluster or co-occur (in this cohort, with the current measures) at this developmental timepoint. Experimental measures that assay underlying neuroendophenotypic processes, continued study of these cohorts as they age, and item-level network analysis approaches to measurement, may all in future studies help answer these questions.

**Key points and relevance**

- We used a broad range of outcome measures to identify the ‘natural categories’ of early atypical outcome in infants with family history of autism and / or ADHD.

- Some infants with a family history of autism and / or ADHD have neurodevelopmental profiles characterised by combinations of either, or both, low developmental level and atypical behaviour but not elevated autism or ADHD traits in isolation.
• The field needs to adopt a transdiagnostic approach in the study of early development in autism and ADHD in order to develop fit-for-purpose developmental models and translational opportunities.

Acknowledgments
The authors are grateful to all the families who took part in this study. The STAARS team consists of: Leila Dafner, Laurel Fish, Teodora Gliga, Rianne Haartsen, Sarah Kalwarowsky, Anna Kolesnik, Sarah Lloyd-Fox, Luke Mason, Laura Pirazzoli, Chloë Taylor. We thank the researchers who assisted with recruitment and data collection of the independent cohort: Anna Blasi, Kim Davies, Mayada Elsabbagh, Janice Fernandes, Isobel Gammer, Jeanne Guiraud, Michelle Liew, Helen Maris, Louise O’Hara, Helena Ribeiro, Erica Salomone, Leslie Tucker. For the purposes of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Accepted Author Manuscript version arising from this submission.

Author Contributions
TC, MHJ, AP and EJHJ obtained funding and designed the study. AH, TB, NN, AG, HH, MA, RH, and ME were involved in conducting the study and/or data collection or analysis. TC and AP conducted the data analysis. The article was drafted by TC and all authors read, made revisions and approved the final version.

Funding
This research was supported by awards from the Medical Research Council (G0701484, MR/K021389/1, MR/T003057/1), the BASIS funding consortium led by Autistica, MQ (MQ14PP_83), EU-AIMS and AIMS-2-TRIALS funded by the Innovative Medicines Initiative (IMI) Joint Undertaking Grant Nos. 115300 and No. 777394. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme, with in-kind contributions from the European Federation of Pharmaceutical Industries and Associations (EFPIA) companies and funding from Autism Speaks, Autistica and SFARI. Capital equipment funding from the Maudsley Charity (980) and Guy’s and St Thomas’ Charity (STR130505). AP acknowledges support from the National Institute for Health Research (NIHR) through NF-SI-0617-10120 and the NIHR Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. AH is supported by an NIHR Advanced Fellowship (NIHR300880). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Conflicts of Interest
TC has served as a paid consultant to F. Hoffmann-La Roche Ltd. and Servier; and has received royalties from Sage Publications and Guilford Publications. AP receives royalties from Western Psychological Services, Imperial College Press, and OUP. MJ receives royalties from Wiley-Blackwell, OUP and MIT Press. EJ is a Joint Editor on JCPP Advances. The remaining authors have declared that they have no competing or potential conflicts of interest.

Ethical Statement
Ethical approval was granted by the National Research Ethics Service (13/LO/0751 and 08/H0718/76) and the Research Ethics Committee, Department of Psychological Sciences, Birkbeck, University of London.

**Data Availability Statement**
Data available following a review of requests as indicated here:
https://www.basisnetwork.org/collaboration-and-project-affiliation/
OUTCOME IN INFANTS WITH A FAMILY HISTORY OF AUTISM AND ADHD

Correspondence
Tony Charman, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, SE5 8AF, UK; e-mail: tony.charman@kcl.ac.uk

References


between ADHD and ASD trait dimensions in young adults: A twin study.

*Psychological Medicine, 49*(10), 1713–1721.

https://doi.org/10.1017/S003329171800243X


and neurodevelopmental disorders in siblings. Psychological Medicine, 49(1), 84–91. https://doi.org/10.1017/S0033291718000521


<table>
<thead>
<tr>
<th></th>
<th>FH-Autism</th>
<th>FH-Autism + ADHD</th>
<th>FH-ADHD</th>
<th>TL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N = 67</td>
<td>N = 16</td>
<td>N = 26</td>
<td>N = 22</td>
</tr>
<tr>
<td>N (%)</td>
<td>N (%)</td>
<td>N (%)</td>
<td>N (%)</td>
<td>N (%)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>32 (48%)</td>
<td>11 (69%)</td>
<td>15 (58%)</td>
<td>13 (59%)</td>
</tr>
<tr>
<td>Female</td>
<td>35 (52%)</td>
<td>5 (31%)</td>
<td>11 (42%)</td>
<td>9 (41%)</td>
</tr>
<tr>
<td>Age in months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>37.21 (1.46)</td>
<td>37.19 (1.52)</td>
<td>37.35 (2.69)</td>
<td>36.79 (1.78)</td>
</tr>
<tr>
<td>Ethnicity (maternal)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White/European/Irish</td>
<td>53 (83%)</td>
<td>14 (93%)</td>
<td>24 (92%)</td>
<td>17 (85%)</td>
</tr>
<tr>
<td>Asian/African/</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>African-Caribbean/Mixed Heritage</td>
<td>11 (17%)</td>
<td>1 (7%)</td>
<td>2 (8%)</td>
<td>3 (15%)</td>
</tr>
<tr>
<td>Maternal Education</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Up to High School/Further Education</td>
<td>19 (30%)</td>
<td>8 (53%)</td>
<td>8 (31%)</td>
<td>1 (5%)</td>
</tr>
<tr>
<td>University Degree or Higher</td>
<td>45 (70%)</td>
<td>7 (47%)</td>
<td>18 (69%)</td>
<td>19 (95%)</td>
</tr>
</tbody>
</table>

FH-Autism = autism family history, FH-Autism + ADHD = autism + ADHD family history, FH-ADHD = ADHD family history, TL = Typical likelihood
### Table 2  
3 Year Developmental and Behavioural Characteristics by LPA Outcome Class – Main Cohort

<table>
<thead>
<tr>
<th>Measure</th>
<th>LDL+HBC(^1) class</th>
<th>LDL+TB(^2) class</th>
<th>TDL+SBC(^3) class</th>
<th>HDL+TB(^4) class</th>
<th>ANOVA</th>
<th>Post-hocs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(N = 20)</td>
<td>(N = 23)</td>
<td>(N = 33)</td>
<td>(N = 55)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(M (SD))</td>
<td>(M (SD))</td>
<td>(M (SD))</td>
<td>(M (SD))</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Measures used to derive LPA outcome classes**

<table>
<thead>
<tr>
<th>Measure</th>
<th>LDL+HBC(^1)</th>
<th>LDL+TB(^2)</th>
<th>TDL+SBC(^3)</th>
<th>HDL+TB(^4)</th>
<th>(F(119,3) = 3.85**)</th>
<th>(4 &gt; 1, 2, 3; 3 &gt; 1, 2; 2 &gt; 1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mullen ELC(^a)</td>
<td>84.38 (11.96)</td>
<td>96.57 (10.72)</td>
<td>114.84 (8.70)</td>
<td>130.19 (8.83)</td>
<td>(F(113,3) = 119.17**)</td>
<td>(4 &gt; 1, 2, 3; 3 &gt; 1, 2; 2 &gt; 1)</td>
</tr>
<tr>
<td>Vineland ABC(^a)</td>
<td>81.52 (10.60)</td>
<td>87.14 (8.27)</td>
<td>94.86 (7.42)</td>
<td>105.17 (7.58)</td>
<td>(F(105,3) = 43.47**)</td>
<td>(4 &gt; 1, 2, 3; 3 &gt; 1, 2)</td>
</tr>
<tr>
<td>ADOS-2 CSS(^b)</td>
<td>3.11 (2.19)</td>
<td>1.83 (1.19)</td>
<td>2.19 (1.38)</td>
<td>1.78 (1.30)</td>
<td>(F(119,3) = 3.97**)</td>
<td>(1 &gt; 2, 4)</td>
</tr>
<tr>
<td>SCQ(^c)</td>
<td>19.63 (7.50)</td>
<td>3.48 (1.99)</td>
<td>6.43 (3.76)</td>
<td>2.25 (1.70)</td>
<td>(F(109,3) = 100.62**)</td>
<td>(1 &gt; 2, 3, 4; 3 &gt; 2, 4)</td>
</tr>
<tr>
<td>CBCL ADHD(^d)</td>
<td>65.24 (7.50)</td>
<td>51.19 (2.66)</td>
<td>55.48 (5.56)</td>
<td>51.02 (2.85)</td>
<td>(F(112,3) = 46.39**)</td>
<td>(1 &gt; 2, 3, 4; 3 &gt; 2, 4)</td>
</tr>
<tr>
<td>Researcher ADHD(^e)</td>
<td>12.67 (2.69)</td>
<td>12.33 (2.24)</td>
<td>11.27 (1.71)</td>
<td>10.96 (2.20)</td>
<td>(F(104,3) = 3.50^*)</td>
<td>(1 &gt; 4)</td>
</tr>
<tr>
<td>CBCL Anxiety(^d)</td>
<td>64.41 (10.08)</td>
<td>50.95 (1.83)</td>
<td>57.33 (7.55)</td>
<td>50.27 (1.02)</td>
<td>(F(112,3) = 35.24**)</td>
<td>(1 &gt; 2, 3, 4; 3 &gt; 2, 4)</td>
</tr>
</tbody>
</table>

**Other measures (not used in the LPA analysis)**

<table>
<thead>
<tr>
<th>Measure</th>
<th>LDL+HBC(^1)</th>
<th>LDL+TB(^2)</th>
<th>TDL+SBC(^3)</th>
<th>HDL+TB(^4)</th>
<th>(F(113,3) = 3.85**)</th>
<th>(4 &gt; 1, 2, 3; 3 &gt; 1, 2; 2 &gt; 1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SRS(^d)</td>
<td>71.47 (13.79)</td>
<td>45.75 (4.83)</td>
<td>52.28 (8.73)</td>
<td>42.17 (3.57)</td>
<td>(F(103,3) = 63.66**)</td>
<td>(1 &gt; 2, 3, 4; 3 &gt; 2, 4)</td>
</tr>
<tr>
<td>ADI-Social(^c)</td>
<td>12.37 (7.33)</td>
<td>2.57 (3.16)</td>
<td>2.81 (3.20)</td>
<td>0.82 (1.01)</td>
<td>(F(118,3) = 47.93**)</td>
<td>(1 &gt; 2, 3, 4)</td>
</tr>
<tr>
<td>ADI-Comm(^c)</td>
<td>8.74 (5.32)</td>
<td>2.83 (3.65)</td>
<td>2.48 (2.61)</td>
<td>0.51 (1.00)</td>
<td>(F(118,3) = 34.64**)</td>
<td>(1 &gt; 2, 3, 4; 2 &gt; 3)</td>
</tr>
<tr>
<td>ADI-RRB(^c)</td>
<td>3.68 (2.31)</td>
<td>0.52 (0.73)</td>
<td>1.61 (1.86)</td>
<td>0.24 (0.69)</td>
<td>(F(118,3) = 29.85**)</td>
<td>(1 &gt; 2, 3, 4; 3 &gt; 2, 4)</td>
</tr>
</tbody>
</table>

\* p<.05, ** p<.01, ***p<.001

1, 2, 3, 4 – Class labels for ANOVA Tukey-Kramer corrected post-hocs

LDL+HBC = Low Developmental Level + High Behavioural Concerns; LDL+TB = Low Developmental Level + Typical Behaviour;

TDL+SBC = Typical Developmental Level + Some Behavioural Concerns; HDL + TB = High Developmental Level + Typical Behaviour

a standard score, b ADOS-2 Calibrated Severity Score, c raw score, d T-score

ELC = Mullen Early Learning Composite, ABC = Vineland Adaptive Behavior Composite, ADOS-2 CSS = ADOS-2 Calibrated Severity Score, SCQ = Social Communication Questionnaire, CBCL = Child Behavior Checklist, SRS = Social Responsiveness Scale, ADI = Autism Diagnostic Interview, Comm = Communication, RRB = Repetitive and Restricted Behaviours
### Table 3  
Number and percentage of each LPA class in atypical range on 36 month characterisation measures – Main Cohort

<table>
<thead>
<tr>
<th>Measure</th>
<th>LDL+HBC class</th>
<th>LDL+TB class</th>
<th>TDL+SBC class</th>
<th>HDL+TB class</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N = 20</td>
<td>N = 23</td>
<td>N = 33</td>
<td>N = 55</td>
</tr>
<tr>
<td>Mullen ELC &lt; 85</td>
<td>7 (44%)</td>
<td>3 (13%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Vineland ABC &lt; 85</td>
<td>12 (71%)</td>
<td>9 (41%)</td>
<td>0 (0%)</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>ADOS CSS ≥ 4</td>
<td>7 (39%)</td>
<td>3 (13%)</td>
<td>7 (23%)</td>
<td>9 (18%)</td>
</tr>
<tr>
<td>SCQ score ≥ 12</td>
<td>15 (88%)</td>
<td>0 (0%)</td>
<td>2 (8%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>ADHD rating</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>CBCL ADHD T-score ≥ 60</td>
<td>15 (88%)</td>
<td>1 (5%)</td>
<td>5 (20%)</td>
<td>2 (4%)</td>
</tr>
<tr>
<td>CBCL Anxiety T-score ≥ 60</td>
<td>12 (71%)</td>
<td>0 (0%)</td>
<td>10 (38%)</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>

LDL+HBC = Low Developmental Level + High Behavioural Concerns; LDL+TB = Low Developmental Level + Typical Behaviour; TDL+SBC = Typical Developmental Level + Some Behavioural Concerns; HDL + TB = High Developmental Level + Typical Behaviour; N/A = Not applicable.  
### Table 4  
**LPA Outcome Class by Familial Likelihood Group and Sex – Main Cohort**

<table>
<thead>
<tr>
<th>Familial likelihood Group</th>
<th>LDL+HBC class</th>
<th>LDL+TB class</th>
<th>TDL+SBC class</th>
<th>HDL+TB class</th>
<th>Total N</th>
</tr>
</thead>
<tbody>
<tr>
<td>TL</td>
<td>N (%)</td>
<td>N (%)</td>
<td>N (%)</td>
<td>N (%)</td>
<td>22 N (%)</td>
</tr>
<tr>
<td>FH-Autism</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>4 (18%)</td>
<td>18 (82%)</td>
<td>22 N (%)</td>
</tr>
<tr>
<td>FH-Autism + ADHD</td>
<td>14 (21%)</td>
<td>15 (22%)</td>
<td>16 (24%)</td>
<td>22 (33%)</td>
<td>67 N (%)</td>
</tr>
<tr>
<td>FH-ADHD</td>
<td>5 (31%)</td>
<td>2 (13%)</td>
<td>6 (38%)</td>
<td>3 (19%)</td>
<td>16 N (%)</td>
</tr>
<tr>
<td></td>
<td>1 (4%)</td>
<td>6 (23%)</td>
<td>7 (27%)</td>
<td>12 (46%)</td>
<td>26 N (%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sex</th>
<th>N (%)</th>
<th>N (%)</th>
<th>N (%)</th>
<th>N (%)</th>
<th>131 N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>13 (65%)</td>
<td>16 (70%)</td>
<td>17 (52%)</td>
<td>25 (45%)</td>
<td>71 N (%)</td>
</tr>
<tr>
<td>Female</td>
<td>7 (35%)</td>
<td>7 (30%)</td>
<td>16 (48%)</td>
<td>30 (55%)</td>
<td>60 N (%)</td>
</tr>
</tbody>
</table>

LDL+HBC = Low Developmental Level + High Behavioural Concerns; LDL+TB = Low Developmental Level + Typical Behaviour; TDL+SBC = Typical Developmental Level + Some Behavioural Concerns; HDL + TB = High Developmental Level + Typical Behaviour
Figure 1  Profile on indicator variables of LPA outcome classes